| Sarah M Gabel, DO | |
|
310 E College Dr, Colby, KS 67701-3716 | |
| (785) 462-6184 | |
| (785) 460-1490 |
| Full Name | Sarah M Gabel |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 16 Years |
| Location | 310 E College Dr, Colby, Kansas |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1255594305 | NPI | - | NPPES |
| 05-36722 | Other | KS | KANSAS LICENSE |
| 201088060A | Medicaid | KS |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 0536722 (Kansas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Citizens Medical Center | Colby, KS | Hospital |
| Colby Operator, Llc | Colby, KS | Nursing home |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Citizens Medical Center Inc | 8729996467 | 30 |
News Archive
Scientists at Johns Hopkins and the University of Texas Medical Branch have created a new tool that easily reveals when and where a key cellular signal is active.
Smoking has been shown to have drastic consequences for lifespan and disease progression, and it has been suggested that cigarette exposure may impact the risk of death and disease via its acceleration of the aging process. Not all smokers experience early mortality, however, and a small proportion manage to survive to extreme ages.
Cambridge Heart, Inc., today announced that it has received clearance from the U.S. Food and Drug Administration to begin marketing its Microvolt T-Wave Alternans (MTWA) OEM module. The MTWA OEM module is designed to work with existing cardiac stress test platforms distributed by other manufacturers. This FDA 510(k) clearance allows Cambridge Heart to begin marketing the MTWA OEM module integrated with the Q-Stress line of stress systems manufactured by Cardiac Science Corporation, Inc..
Existing practice surrounding many cardiovascular medications, including anti-hypertensive and lipid-lowering agents, is based on the evaluation of response to therapy. In cases where ideal therapeutic targets (which have been identified through several previous studies) are not met in the single individual, there is evidence to support the need to intensify standard treatment so as to achieve better control of the cardiovascular risk factor under treatment (e.g. blood pressure or cholesterol levels) as this translates into a better outcome.
Advanced Cell Technology, Inc. or "ACT" reported that a range of therapeutic cell types obtained from induced pluripotent stem (iPS) cells exhibit abnormal expansion and early cellular aging. The research, which appears online (published-ahead-of- print) in the journal STEM CELLS by ACT and its collaborators at Stem International (SCRMI), Harvard Medical School, and the University of Illinois, compares a variety of replacement cell types derived from human iPS cells with their embryonic stem (ES) cell counterparts. The findings support the use of ACT's single blastomere-derived human embryonic stem cell lines which do not display early aging.
› Verified 7 days ago
| Entity Name | Citizens Medical Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1386678431 PECOS PAC ID: 8729996467 Enrollment ID: O20031222000868 |
News Archive
Scientists at Johns Hopkins and the University of Texas Medical Branch have created a new tool that easily reveals when and where a key cellular signal is active.
Smoking has been shown to have drastic consequences for lifespan and disease progression, and it has been suggested that cigarette exposure may impact the risk of death and disease via its acceleration of the aging process. Not all smokers experience early mortality, however, and a small proportion manage to survive to extreme ages.
Cambridge Heart, Inc., today announced that it has received clearance from the U.S. Food and Drug Administration to begin marketing its Microvolt T-Wave Alternans (MTWA) OEM module. The MTWA OEM module is designed to work with existing cardiac stress test platforms distributed by other manufacturers. This FDA 510(k) clearance allows Cambridge Heart to begin marketing the MTWA OEM module integrated with the Q-Stress line of stress systems manufactured by Cardiac Science Corporation, Inc..
Existing practice surrounding many cardiovascular medications, including anti-hypertensive and lipid-lowering agents, is based on the evaluation of response to therapy. In cases where ideal therapeutic targets (which have been identified through several previous studies) are not met in the single individual, there is evidence to support the need to intensify standard treatment so as to achieve better control of the cardiovascular risk factor under treatment (e.g. blood pressure or cholesterol levels) as this translates into a better outcome.
Advanced Cell Technology, Inc. or "ACT" reported that a range of therapeutic cell types obtained from induced pluripotent stem (iPS) cells exhibit abnormal expansion and early cellular aging. The research, which appears online (published-ahead-of- print) in the journal STEM CELLS by ACT and its collaborators at Stem International (SCRMI), Harvard Medical School, and the University of Illinois, compares a variety of replacement cell types derived from human iPS cells with their embryonic stem (ES) cell counterparts. The findings support the use of ACT's single blastomere-derived human embryonic stem cell lines which do not display early aging.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Sarah M Gabel, DO 310 E College Dr, Colby, KS 67701-3716 Ph: (785) 462-6184 | Sarah M Gabel, DO 310 E College Dr, Colby, KS 67701-3716 Ph: (785) 462-6184 |
News Archive
Scientists at Johns Hopkins and the University of Texas Medical Branch have created a new tool that easily reveals when and where a key cellular signal is active.
Smoking has been shown to have drastic consequences for lifespan and disease progression, and it has been suggested that cigarette exposure may impact the risk of death and disease via its acceleration of the aging process. Not all smokers experience early mortality, however, and a small proportion manage to survive to extreme ages.
Cambridge Heart, Inc., today announced that it has received clearance from the U.S. Food and Drug Administration to begin marketing its Microvolt T-Wave Alternans (MTWA) OEM module. The MTWA OEM module is designed to work with existing cardiac stress test platforms distributed by other manufacturers. This FDA 510(k) clearance allows Cambridge Heart to begin marketing the MTWA OEM module integrated with the Q-Stress line of stress systems manufactured by Cardiac Science Corporation, Inc..
Existing practice surrounding many cardiovascular medications, including anti-hypertensive and lipid-lowering agents, is based on the evaluation of response to therapy. In cases where ideal therapeutic targets (which have been identified through several previous studies) are not met in the single individual, there is evidence to support the need to intensify standard treatment so as to achieve better control of the cardiovascular risk factor under treatment (e.g. blood pressure or cholesterol levels) as this translates into a better outcome.
Advanced Cell Technology, Inc. or "ACT" reported that a range of therapeutic cell types obtained from induced pluripotent stem (iPS) cells exhibit abnormal expansion and early cellular aging. The research, which appears online (published-ahead-of- print) in the journal STEM CELLS by ACT and its collaborators at Stem International (SCRMI), Harvard Medical School, and the University of Illinois, compares a variety of replacement cell types derived from human iPS cells with their embryonic stem (ES) cell counterparts. The findings support the use of ACT's single blastomere-derived human embryonic stem cell lines which do not display early aging.
› Verified 7 days ago
Dr. Darren R Matchell, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 310 E College Dr, Colby, KS 67701 Phone: 785-462-6184 Fax: 785-460-1490 | |
Kysha C Nichols-totten, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 310 E College Dr, Colby, KS 67701 Phone: 785-462-6184 Fax: 785-460-1490 | |
Dereck D Totten, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 310 E College Dr, Colby, KS 67701 Phone: 785-462-6184 Fax: 785-460-1490 | |
Daniel P Kuhlman, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 310 E College Dr, Colby, KS 67701 Phone: 785-462-6184 Fax: 785-460-1490 | |
Kara S Kuhlman, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 310 E College Dr, Colby, KS 67701 Phone: 785-462-6184 Fax: 785-460-1490 | |
Dr. Michael D Nordquist, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 310 E College Dr, Colby, KS 67701 Phone: 785-462-6184 Fax: 785-460-1490 |